Komori
ReproCELL (4978) · TargetSoftened

Fiscal year ending March 2023: net sales of ¥3,565 million and ordinary profit of ¥491 million

First written in FY2020. 4 of 6 entries say "Softened", first in FY2023. Latest entry: FY2026.

6entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020SoftenedFY2021 – FY20262020: 120202021: 120212022: 020222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 791 companies write about · 75 as a headwind · 1062 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1182 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026SoftenedAnnual report

    「For the fiscal year ending March 2027, the company forecasts net sales of ¥2,629 million, up 17.7% from the current fiscal year, an operating loss of ¥630 million, compared with a loss of ¥860 million in the current fiscal year, an ordinary loss of ¥458 million, compared with a loss of ¥581 million, and a net loss attributable to owners of the parent of ¥458 million, compared with a loss of ¥591 million.」

    For FY2027, the company has presented a forecast of higher net sales and narrower losses, although operating, ordinary and net losses are expected to continue.
  2. FY2025SoftenedAnnual report

    「For the fiscal year ending March 2026, the company forecasts net sales of ¥3,037 million, up 2.0% from the current fiscal year, an operating loss of ¥268 million, compared with a loss of ¥130 million in the current fiscal year, an ordinary loss of ¥75 million, compared with ordinary profit of ¥45 million, and a net loss attributable to owners of the parent of ¥75 million, compared with net income of ¥103 million.」

    For the following fiscal year, the company expects higher net sales but forecasts a shift to an operating loss, ordinary loss and net loss, weakening its earnings outlook from FY2025, when ordinary profit and net income were expected to be positive.
  3. FY2024SoftenedAnnual report

    「For the fiscal year ending March 2025, the company forecasts net sales of ¥2,661 million, up 9.7% from the current fiscal year, an operating loss of ¥325 million, compared with a loss of ¥409 million in the current fiscal year, an ordinary loss of ¥174 million, compared with ordinary profit of ¥40 million, and a net loss attributable to owners of the parent of ¥174 million, compared with a loss of ¥31 million.」

    For the fiscal year ending March 2025, the company expects higher sales and a smaller operating loss, while forecasting a return to an ordinary loss and net loss after ordinary profit and a reduced net loss in the current fiscal year.
  4. FY2023SoftenedAnnual report

    「For the fiscal year ending March 2024, the company forecasts net sales of ¥3,048 million, up 3.2% from the current fiscal year, an operating loss of ¥110 million, compared with a loss of ¥356 million in the current fiscal year, ordinary profit of ¥148 million, compared with a loss of ¥119 million, and net income attributable to owners of the parent of ¥148 million, compared with a loss of ¥305 million.」

    The FY2024 forecast has been reduced from the FY2021 target for the fiscal year ending March 2024 of ¥4,065 million in net sales and ¥760 million in ordinary profit to ¥3,048 million and ¥148 million, respectively. While an operating loss is still expected, the company forecasts a return to profitability for ordinary profit and net income.
  5. FY2021ReframedAnnual report

    「For the fiscal year ending March 2024, the third year of the medium-term management plan (fiscal years ending March 2022 to March 2024), the targets are net sales of ¥4,065 million and ordinary profit of ¥760 million.」

    The company updated the target time frame and figures from the previous target for the fiscal year ending March 2023 to a new medium-term management plan with the fiscal year ending March 2024 as its third year.
  6. FY2020First statedAnnual report

    「For the fiscal year ending March 2023, the third year of the medium-term management plan (fiscal years ending March 2021 to March 2023), the targets are net sales of ¥3,565 million and ordinary profit of ¥491 million.」

    The company disclosed for the first time its net sales and ordinary profit targets for the medium-term management plan ending in the fiscal year ending March 2023.
Moved together

"Impairment Risk for Goodwill and Intangible Assets at Overseas Subsidiaries" moved the same way as this thread, in the same document, in 4 of its 6 moves.

4332★1234
  1. ★This thread
  2. 1Impairment Risk for Goodwill and Intangible Assets at Overseas Subsidiaries4×
  3. 2Persistent losses as upfront investment and R&D expenses precede revenue generation3×
  4. 3Risk of Future Tax Burden from Tax Loss Carryforwards3×
  5. 4Risk of delayed elimination of accumulated deficits2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Fiscal year ending March 2023: net sales of ¥3,565 million and ordinary profit of ¥491 million | ReproCELL Incorporated (4978) | Komori